
|Videos|January 28, 2016
Dr. Susan Panullo on Optune Versus Salvage Chemotherapy in Glioblastoma
Author(s)Susan Panullo, MD
Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A).
Advertisement
Susan Panullo, MD, director, Neuro-oncology, director, Neurosurgical Radiosurgery, Weill Cornell Brain and Spine Center, discusses the improvement in quality of life in patients with glioblastoma treated with Optune (NovoTTF-100A). Panullo says patients treated with Optune versus patients treated with salvage chemotherapy both lived the same amount of time, with the former's quality of life being much better than the latter's.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Allogeneic CD70 CAR T-Cell Therapy Shows Activity in Refractory Kidney Cancer
2
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
3
Pembrolizumab Plus Denosumab Shows Activity in Pretreated Kidney Cancer
4
Final RELEVANCE Data Affirm R2 as Chemo-Free Alternative in Untreated FL
5



























